SCHEMBL1733664

SCHEMBL1733664

CNc1nc(C(N)=O)cc(-c2ccccc2)n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.65
KDM4E B2RXH2 5/20 0.57
GLA P06280 2/20 0.53
HTT P42858 2/20 0.53
ADORA1 P30542 8/20 0.53
ADORA3 P0DMS8 2/20 0.53
ALDH1A1 P00352 3/20 0.52
HSD17B10 Q99714 3/20 0.52
HPGD P15428 2/20 0.52
GAA P10253 1/20 0.52
TSHR P16473 1/20 0.52
CASP1 P29466 1/20 0.52
CASP7 P55210 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
LMNA P02545 1/20 0.50
POLB P06746 1/20 0.50
GPR55 Q9Y2T6 1/20 0.50
MAPK1 P28482 1/20 0.49
ADORA2A P29274 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1734290 0.85 TDP1 (0.65) TDP1ADORA1ADORA3SMN1; SMN2ADORA2A
SCHEMBL1733671 0.84 KDM4E (0.53) TDP1KDM4EGLAHTTADORA1
SCHEMBL1733575 0.84 FPR2 (0.55) TDP1KDM4EGLAHTTADORA1
SCHEMBL1734332 0.84 KDM4E (0.60) KDM4EGLAHTTADORA1ADORA3
SCHEMBL3724700 0.83 SCN9A (0.51) TDP1ADORA3CASP1FPR2SCN9A
SCHEMBL1733359 0.83 ADORA1 (0.50) GLAHTTADORA1ADORA3ALDH1A1
SCHEMBL1734127 0.82 KDM4E (0.57) KDM4EGLAHTTADORA1ADORA3
SCHEMBL1734267 0.81 PIK3CB (0.57) KDM4EGLAHTTALDH1A1HSD17B10
SCHEMBL1734467 0.81 KDM4E (0.53) KDM4EGLAHTTADORA1ADORA3
SCHEMBL1734424 0.81 KDM4E (0.53) KDM4EGLAHTTADORA1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP claimed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO claimed
EP-1891018-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals, Inc. (US) 2008-02-27 EP claimed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US claimed
WO-2006127588-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-11-30 WO claimed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 TDP1 3350/4885KDM4E 3910/4885GLA 4678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.